When sequencing bispecific antibodies after a BCMA-targeted agent fails, clinicians prefer the FCRH5-targeting Cevostamab over the GPRC5D-targeting Talquetamab. This choice is driven primarily by Cevostamab's more manageable toxicity profile and lower infection signal.
To determine why a BCMA-targeted therapy failed, clinicians are using plasma sequencing assays to check for mutations in the BCMA receptor. The presence of a mutation prompts a switch to a different target rather than retrying a BCMA-directed agent.
Experts now view a patient's response to bridging therapy as a key predictor of CAR T outcomes. A patient who fails to respond or progresses during bridging has a much higher risk of toxicity and poor efficacy and should be considered for alternative treatments.
As frontline therapies improve and create longer remissions, the first relapse becomes the pivotal moment for treatment. Experts advocate for treating this stage with the same intensity and goals as newly diagnosed disease, including aiming for MRD negativity.
Published data from top cancer centers indicates a real-world treatment-related mortality (TRM) rate of 10% for Siltacel CAR T therapy. This figure is higher than reported in pivotal trials and underscores the significant risks of managing these patients outside of a controlled study.
Clinicians report significant and durable responses using Belantamab in patients who have relapsed after BCMA-targeted CAR-T. This success may be due to Belantamab's immunogenic mechanism, which doesn't rely on endogenous T-cells and may favorably interact with the post-CAR immune environment.
Administering tocilizumab before the first bispecific antibody dose significantly reduces Cytokine Release Syndrome (CRS) risk. This proactive strategy enables safer outpatient treatment, lowering hospital admissions and improving patient access, especially in community settings.
Belantamab's primary mechanism, immunogenic cell death, does not exhaust T-cells. This unique quality allows clinicians to use it as a first BCMA-targeted agent without compromising the efficacy of subsequent T-cell redirecting therapies like CAR T or bispecifics.
Beyond their direct anti-myeloma effects, CELMoDs potently activate the immune system. This positions them as ideal partners for immunotherapies like CAR T and bispecifics, with the potential to restore immune function and overcome resistance to T-cell redirecting therapies.
To manage infection risk and improve quality of life, experts are quickly reducing bispecific antibody dosing frequency (e.g., to monthly) once a response is achieved. This real-world practice deviates from rigid trial schedules to optimize patient outcomes.
Clinicians mitigate Belantamab's ocular toxicity by extending dosing intervals to every 8-12 weeks. This is effective due to the drug's long half-life and often allows vision to recover between doses, sometimes even deepening responses without sacrificing disease control.
Chronological age alone should not disqualify older patients from CAR T therapy. Experts successfully treat fit, motivated octogenarians with Siltacel, emphasizing that performance status, motivation, and disease control are more critical factors than age.